At Celldex, we are committed to developing safe and effective therapies for patients with devastating diseases for which available treatments are inadequate.

We understand the importance of bringing these therapies to the broadest group of patients as quickly as possible. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.

Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory review and potential approval.

To learn more about our ongoing clinical trials or to find out if a study is enrolling patients in your area, please visit or email .

Visit here to learn more about our Compassionate Use or Expanded Access Program.

Candidate Phase Identifier Indication
Barzolvolimab Phase 2 [Completed Enrollment] External link opents in a new window NCT05368285 Chronic Spontaneous Urticaria
Barzolvolimab Phase 2 External link opents in a new window NCT05405660 Chronic Inducible Urticaria (Cold Contact Urticaria, Symptomatic Dermographism)
Barzolvolimab Phase 2 External link opents in a new window NCT05774184 Eosinophilic Esophagitis